Company intelligence / Profile preview
GangaGen
Bangalore, Karnataka, Indiagangagen.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Lead ectolysin P128 has advanced to human clinical trials for decolonization of Methicillin Resistant Staphylococcus aureus from human nares in 2015. Klebicins program has obtained encouraging in vivo efficacy data for treatment of K. pneumoniae infections.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Protein AntibacterialsEctolysinsBacteriocinsTherapeutic proteins
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
CARB-X
Beyond the preview
Go deeper on GangaGen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GangaGen.